The average one-year price target for Scilex Holding (NasdaqCM:SCLX) has been revised to $324.27 / share. This is an increase of 2,885.13% from the prior estimate of $10.86 dated March 30, 2025.

The price target is an average of many targets provided by analysts. The latest targets range from a low of $220.94 to a high of $514.50 / share. The average price target represents an increase of 7,887.06% from the latest reported closing price of $4.06 / share.

What is the Fund Sentiment?

There are 178 funds or institutions reporting positions in Scilex Holding. This is an decrease of 6 owner(s) or 3.26% in the last quarter. Average portfolio weight of all funds dedicated to SCLX is 0.00%, an increase of 52.05%. Total shares owned by institutions increased in the last three months by 41.93% to 51,331K shares. The put/call ratio of SCLX is 0.02, indicating a bullish outlook.

What are Other Shareholders Doing?

Armistice Capital holds 17,877K shares representing 341.46% ownership of the company. In its prior filing, the firm reported owning 3,510K shares , representing an increase of 80.37%. The firm increased its portfolio allocation in SCLX by 91.15% over the last quarter.

XBI - SPDR(R) S&P(R) Biotech ETF holds 5,939K shares representing 113.43% ownership of the company. No change in the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 3,712K shares representing 70.90% ownership of the company. No change in the last quarter.

VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 2,095K shares representing 40.01% ownership of the company. In its prior filing, the firm reported owning 2,213K shares , representing a decrease of 5.65%. The firm decreased its portfolio allocation in SCLX by 57.90% over the last quarter.

Northern Trust holds 1,274K shares representing 24.33% ownership of the company. In its prior filing, the firm reported owning 777K shares , representing an increase of 39.03%. The firm decreased its portfolio allocation in SCLX by 81.51% over the last quarter.